PCM
CRNX icon

Prelude Capital Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Prelude Capital Management’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-18,328
Closed -$527K – 1183
2025
Q2 		$527K Buy
18,328
+5,369
+41% +$166K 0.05% 426
2025
Q1 		$435K Buy
+12,959
New +$484K 0.03% 559

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Prelude Capital Management's CRNX Position: Q3 2025 in Review

Prelude Capital Management sold out of Crinetics Pharmaceuticals (CRNX) in Q3 2025, closing a stake of 18,328 shares — an estimated $527K sold.

Prelude Capital Management first reported a position in CRNX in Q1 2025 and held it in 2 quarters. The position peaked at $527K in Q2 2025. 225 funds tracked by Wall St. Rank hold CRNX as of Q3 2025.

  • Prelude Capital Management reported no remaining Crinetics Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Prelude Capital Management sold 18,328 Crinetics Pharmaceuticals shares in Q3 2025, an estimated $527K.
  • Prelude Capital Management first reported a position in Crinetics Pharmaceuticals in Q1 2025 and held it in 2 quarters.
  • Prelude Capital Management's Crinetics Pharmaceuticals position peaked at $527K in Q2 2025.
  • 225 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q3 2025.

Based on Prelude Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.